TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Endometrial Local Injury Improves the Pregnancy Rate Among Recurrent Implantation Failure Patients Undergoing IVF/ICSI
Brief Summary: The purpose of this study is to evaluate the influence of endometrial biopsy on increasing implantation rate in patients with recurrent implantation failures, 93 women with at least two implantation failures were evaluated. In case group endometrial biopsy was obtained from 48 patients in the luteal phase of previous cycle and implantation and clinical pregnancy rate were compared with 45 patients in control group. The results suggest that in vitro fertilization or intracytoplasmic sperm injection after endometrial biopsy increase pregnancy outcome.


Options:
A: Clinical pregnancy rate. (one year); Miscarriage rate. (one year); Multiple pregnancy rates (one year)
B: A difference in the term (37 completed weeks of gestation), singleton live birth rate in women undergoing IVF/ICSI treatment following endometrial biopsy versus control subjects. (Approximately 9 months after completion of the last procedure of the last study participant.)
C: PRIMARY OUTCOME MEASURE:IMPLANTATION RATE; (9 MONTHS)
D: Implantation Rate,Chemical pregnancy rate, Clinical pregnancy rate (One year)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Endometrial Local Injury Improves the Pregnancy Rate Among Recurrent Implantation Failure Patients Undergoing IVF/ICSI
Brief Summary: The purpose of this study is to evaluate the influence of endometrial biopsy on increasing implantation rate in patients with recurrent implantation failures, 93 women with at least two implantation failures were evaluated. In case group endometrial biopsy was obtained from 48 patients in the luteal phase of previous cycle and implantation and clinical pregnancy rate were compared with 45 patients in control group. The results suggest that in vitro fertilization or intracytoplasmic sperm injection after endometrial biopsy increase pregnancy outcome.


Options:
A: Implantation Rate,Chemical pregnancy rate, Clinical pregnancy rate (One year)
B: Implantation ratio (Six months); Clinical pregnancy ratio (six months); Live birth ratio (six months)
C: ongoing pregnancy rate (1 year)
D: Multiple Gestation Rate Following Recruitment of Multiple Follicular Development With an AI, as Compared to CC and FSH. (Participants were followed for the duration of their treatment and, if pregnant through 6 weeks post-delivery, up to 66 weeks)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Endometrial Local Injury Improves the Pregnancy Rate Among Recurrent Implantation Failure Patients Undergoing IVF/ICSI
Brief Summary: The purpose of this study is to evaluate the influence of endometrial biopsy on increasing implantation rate in patients with recurrent implantation failures, 93 women with at least two implantation failures were evaluated. In case group endometrial biopsy was obtained from 48 patients in the luteal phase of previous cycle and implantation and clinical pregnancy rate were compared with 45 patients in control group. The results suggest that in vitro fertilization or intracytoplasmic sperm injection after endometrial biopsy increase pregnancy outcome.


Options:
A: A difference in the term (37 completed weeks of gestation), singleton live birth rate in women undergoing IVF/ICSI treatment following endometrial biopsy versus control subjects. (Approximately 9 months after completion of the last procedure of the last study participant.)
B: Implantation Rate,Chemical pregnancy rate, Clinical pregnancy rate (One year)
C: Ongoing pregnancy (Gestational week 20)
D: Ongoing Pregnancy (Gestational Age of 20 Weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Endometrial Local Injury Improves the Pregnancy Rate Among Recurrent Implantation Failure Patients Undergoing IVF/ICSI
Brief Summary: The purpose of this study is to evaluate the influence of endometrial biopsy on increasing implantation rate in patients with recurrent implantation failures, 93 women with at least two implantation failures were evaluated. In case group endometrial biopsy was obtained from 48 patients in the luteal phase of previous cycle and implantation and clinical pregnancy rate were compared with 45 patients in control group. The results suggest that in vitro fertilization or intracytoplasmic sperm injection after endometrial biopsy increase pregnancy outcome.


Options:
A: Implantation Rate,Chemical pregnancy rate, Clinical pregnancy rate (One year)
B: Intra-uterine pregnancy with fetal heart beat at 10 weeks (10 weeks post ET day)
C: PRIMARY OUTCOME MEASURE:IMPLANTATION RATE; (9 MONTHS)
D: Ongoing pregnancy with fetal heart beat at 10 weeks (10 weeks post ET day)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Adverse Effects of RBC Transfusions: A Unifying Hypothesis
Brief Summary: Transfusion of red blood cells is often used in critically ill patients with low red blood cell counts to prevent disease progression and death. Recent studies suggest that the use of "aged" versus "fresh" red blood cells are associated with worse clinical outcomes. There is evidence that red blood cells work with the cells lining our blood vessels to produce a variety of substances that normally cause arteries to relax and increase blood supply. Two of these substances are called nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF). The investigators are trying to determine the nature of these substances in human beings when they are transfused "aged" versus "fresh" red blood cells. It is their thought that "aged" red blood cells have less of the substances (NO and EDHF) that naturally relax our arteries and further changes the blood supply. One way to determine this is to transfuse a subject's own "aged" and "fresh" red blood cells and inject substances such as L-NMMA (L-NG monomethyl arginine) and TEA (tetraethylammonium chloride), which block the production of NO and EDHF respectively, and then, study what happens to the blood flow.

There is evidence that red blood cells produce NO, which normally causes arteries to relax and increase blood supply. The investigators will try to determine the nature of NO in red blood cells and whether the amount of this substance is altered because of different blood processing and storage techniques. It is their thought that "aged" red blood cells have less NO that naturally relaxes our arteries and further changes the blood supply. This study is designed to determine the most ideal way of storing and processing blood.


Options:
A: Mortality at Day 90 (90 Day)
B: Microcirculatory Flow Index (MFI) before and after blood transfusion. (One hour after the end of blood transfusion compared with before blood transfusion)
C: The Effects of Storage-related RBC Changes on Acetylcholine-stimulated (NO-mediated) Forearm Blood Flow. (5 years)
D: Effect of blood storage age on the resolution of lactic acidosis in children with severe malarial anemia at Mulago hospital (4hrs)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Interactions Between Physical Activity and Cannabis Use in Adults
Brief Summary: In this study the investigators will explore the relationship between physical activity and cannabis use. The investigators will compare regional brain activation detected by imaging technique(fRMI) before and after exercise in cannabis users and compare results with results from controls. The investigators hypothesize that the regional brain activation in response to visual cues (pictures related to cannabis use and food) will be different in cannabis users than in controls and that exercise will significantly alter brain responses to the cues.


Options:
A: Health of Nations Outcome Scale (HONOS) (Baseline, 6 months, 12 months, 18 months,)
B: Craving for cannabis (1 hour)
C: - total quit rates, defined as no evidence of cannabis use during the past 4 weeks as evidenced by self report and a negative urine screen; number of times a cannabis product was used in the past 4 weeks; ; decrease in ASI total score; retention rate
D: Use of illicit drugs in the past 30 days (baseline, 3, 6, 9, and 12 months); Enrollment in formal substance abuse treatment (baseline up to 2 years post-intervention); Medical, legal, employment, social, and psychiatric outcomes (baseline, 3, 6, 9, and 12 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Evaluation of the Efficacy of Spa Treatment for Prevention of Leg Ulcers in Advanced Chronic Venous Insufficiency.
Brief Summary: The main objective of this study is to test the hypothesis that a 3 week intensive course of spa therapy can reduce the risk of leg ulcers in patients with advanced chronic venous insufficiency (C4a-b and C5 of the CEAP classification) at one year.


Options:
A: The Chronic Venous Insufficiency Questionnaire-20 (CIVIQ-20) (12 months); Photoplethysmograph (PPG) (12 months)
B: number of patient with 20% improvement of CIVIC scale at 3 months (3 months)
C: Feasibility as Measured by Number of Participants Who Meet Study Eligibility Criteria at Baseline (Baseline); Number of Screened Subjects Who Provided Consent at Baseline (Baseline); Mean Number of Participants Who Adhered to the Assigned Physical Activity During 8-week Period (Intervention Arm -FitBit Arm ) (8 weeks); Mean Physical Activity Questionnaire Score at 3 Months (Standard of Care Arm Only) (3 months); Mean Physical Activity Questionnaire Score at 6 Months (Standard of Care Arm Only) (6 months); Mean Physical Activity Questionnaire Score at 9 Months (Standard of Care Arm Only) (9 months); Proportion of Subjects Who Complete Post-randomization (Within 24 months of trial initiation)
D: Occurrence of a leg ulcer within the year following the inclusion. The ulcer will be classified C5 of CEAP (healed ulcer) or C6 (non healed ulcer)at the follow up visit. (1 year)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: An Open-label, Multi-center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (AHUS)
Brief Summary: The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).


Options:
A: Platelet Count Change From Baseline to 26 Weeks (From Baseline to 26 weeks); Percentage of Patients With Platelet Count Normalization (Through 26 weeks); Percentage of Patients With Hematologic Normalization (Through 26 weeks)
B: The effect of OMS721 as measured by platelet count change from baseline (26 weeks)
C: Percentage of Patients With TMA Event-free Status (Through 26 weeks); Percentage of Patients With Hematologic Normalization (Through 26 weeks); Percentage of Patients With Complete TMA Response (Through 26 weeks)
D: Percentage of Patients With TMA Event-free Status (Through 26 weeks); Percentage of Patients With Hematologic Normalization (Through 26 weeks); Percentage of Patients With Complete TMA Response (Through 26 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: An Open-label, Multi-center Controlled Clinical Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (AHUS)
Brief Summary: The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).


Options:
A: Percentage of Patients With TMA Event-free Status (Through 26 weeks); Percentage of Patients With Hematologic Normalization (Through 26 weeks); Percentage of Patients With Complete TMA Response (Through 26 weeks)
B: [Safety] Expressed frequency and severity of incidence of AE/SAEs after treatment with investigational product. (6 months); [Efficacy] Proportion of subjects who reach a score of FG2 or lower on the Hughes functional grading scale at week 4（Response Rate） (4 weeks)
C: Comparison of the Responder Rates Between Two Treatment Groups in the Efficacy Period (6 months)
D: Percentage of Patients With TMA Event-free Status (Through 26 weeks); Percentage of Patients With Hematologic Normalization (Through 26 weeks); Percentage of Patients With Complete TMA Response (Through 26 weeks)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: MN-221-CL-007: A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MN-221 When Administered Intravenously as an Adjunct to Standard Therapy to Adults With an Acute Exacerbation of Asthma
Brief Summary: The objective of this clinical study is to examine the safety and effectiveness of intravenous MN-221 compared to placebo when administered as an adjunct to standard therapy in subjects experiencing an acute exacerbation of asthma.


Options:
A: Spirometry (6 months)
B: Change in Pulmonary Asthma Score (PAS) (0-30 minutes)
C: The primary efficacy analysis will be based on a change in FEV1, expressed as percent of predicted, at Hour 3 when compared to FEV1, expressed as percent of predicted, at the qualifying/screening timepoint. (Hour 3)
D: The Time-weighted Average of Change in Forced Expiratory Volume in One Second (FEV1) (baseline over the first 60 minutes)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus
Brief Summary: The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.


Options:
A: Major Adverse Cardiovascular Events (MACE) Composite of Cardiovascular (CV) Death, Non-Fatal Myocardial Infarction (MI), and Non-Fatal Stroke (Up to approximately 8 years)
B: Change in HbA1c From Baseline to Week 26 (Main Study) (Day 1 (Baseline) and Week 26); Change in HbA1c From Baseline to Week 26 (High Glycemic Substudy) (Day 1 (Baseline) and Week 26)
C: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104 (Baseline and Week 104)
D: A composite endpoint including: all-causes mortality, non fatal myocardial infarction (MI) - including silent MI- , non fatal stroke, unplanned coronary revascularization (48 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Open-label, Parallel-group, Multicenter Study to Determine the Efficacy and Long-term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus.
Brief Summary: A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.


Options:
A: Change in Glycosylated Haemoglobin A1c (HbA1c) (week 0, week 16)
B: Change From Baseline in Hemoglobin A1C at Week 54 (Baseline and Week 54); Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue (Up to Week 57); Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue (Up to Week 54)
C: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 (Baseline and Week 52)
D: Incidence of liver inflammation or injury greater than 3 times the upper limit of normal, as monitored by serum alanine aminotransaminase elevation. (At All Visits)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Controlled Trial of Acupuncture for Residual Insomnia Associated With Major Depressive Disorder
Brief Summary: The purpose of this study is to evaluate the clinical effectiveness of acupuncture treatment on residual insomnia in major depressive patients.


Options:
A: Self-rated sleep quality score changes from baseline to 5-week posttreatment measured by Insomnia Severity Index questionnaire (Baseline, 1-week and 5-week posttreatment.)
B: HAMD-17, GDS , BI and CGI (28-day (course of treatment))
C: Self-rated sleep quality score measured by Insomnia Severity Index questionnaire (Baseline, weekly during the treatment course, 1-week and 4-week posttreatment.); Sleep parameters (sleep onset latency, sleep efficiency, total sleep time, times of wakening during sleep) by objective measure - wrist actigraphy (Baseline, 1-week posttreatment, and 4-week posttreatment.); Sleep parameters (sleep onset latency, sleep efficiency, total sleep time, times of wakening during sleep) by subjective measures using sleep log. (Baseline, weekly during the treatment course, 1-week and 4-week posttreatment.)
D: MDI depression score (3 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation
Brief Summary: The aim of this study is to evaluate the effect of prolonged administration of albumin and midodrine on the prevention of complications (renal failure, sepsis, hemorrhage, hepatic encephalopathy and hyponatremia) in patients with cirrhosis in the waiting list for liver transplantation. One hundred and ninety four patients with cirrhosis and awaiting a liver transplantation will include in the study. Patients will be randomized to receive albumin and midodrine (treatment group) or administration of placebo (saline for albumine) and tablets with excipients without midodrine (control group). Patients will be followed-up during 12th months. In the treatment group albumin will be given at a dose of 40g every 15 days and midodrine 5mg tid, in addition with lactitol (conventional doses) and the specific treatment that patients require by cirrhosis. The group control will receive placebo in the same way than the treatment group in addition with lactitol and the specific treatment that they require by their disease. In all the patients liver and renal function test, hormones determination (renin, aldosterone, noradrenaline), and cytokines will be determined in basal conditions. All these determinations will be repeated at month 1st,3rd, 6th and 12th months. Before the inclusion in the study neuropsychological test and critical flicker test will be performed to diagnose minimum EH. These tests will be repeated at 3rd, 6th and 12th months. All the determinations will be repeated at any time that the patients develop any complication considered as an end point. In baseline conditions and at 3rd and 6th months a questionnaire of quality of life (SF36) will be performed. During a year of follow-up the number of paracentesis that patients require, the incidence of renal failure and EH and their relationship with hormonal activity and cytokine levels, free transplant survival and quality of life will be recorded.


Options:
A: To evaluate complications (renal failure, hepatic encephalopathy, hyponatremia, infection and gastrointestinal bleeding) in patients with cirrhosis awaiting for liver transplant. (When 97 patients are included (% of the whole population))
B: Mortality (18 months)
C: Paracentesis free survival (6 months)
D: Number of patients with control of ascites (3 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation
Brief Summary: The aim of this study is to evaluate the effect of prolonged administration of albumin and midodrine on the prevention of complications (renal failure, sepsis, hemorrhage, hepatic encephalopathy and hyponatremia) in patients with cirrhosis in the waiting list for liver transplantation. One hundred and ninety four patients with cirrhosis and awaiting a liver transplantation will include in the study. Patients will be randomized to receive albumin and midodrine (treatment group) or administration of placebo (saline for albumine) and tablets with excipients without midodrine (control group). Patients will be followed-up during 12th months. In the treatment group albumin will be given at a dose of 40g every 15 days and midodrine 5mg tid, in addition with lactitol (conventional doses) and the specific treatment that patients require by cirrhosis. The group control will receive placebo in the same way than the treatment group in addition with lactitol and the specific treatment that they require by their disease. In all the patients liver and renal function test, hormones determination (renin, aldosterone, noradrenaline), and cytokines will be determined in basal conditions. All these determinations will be repeated at month 1st,3rd, 6th and 12th months. Before the inclusion in the study neuropsychological test and critical flicker test will be performed to diagnose minimum EH. These tests will be repeated at 3rd, 6th and 12th months. All the determinations will be repeated at any time that the patients develop any complication considered as an end point. In baseline conditions and at 3rd and 6th months a questionnaire of quality of life (SF36) will be performed. During a year of follow-up the number of paracentesis that patients require, the incidence of renal failure and EH and their relationship with hormonal activity and cytokine levels, free transplant survival and quality of life will be recorded.


Options:
A: Mortality or dialysis-dependency (90 days)
B: Renal failure rate (at 3 months)
C: To evaluate complications (renal failure, hepatic encephalopathy, hyponatremia, infection and gastrointestinal bleeding) in patients with cirrhosis awaiting for liver transplant. (When 97 patients are included (% of the whole population))
D: renin-angiotensin-aldosterone activation (4-6 days)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Bronchoscopy Under Titrated Sedation With Propofol or Midazolam: a Randomized Trial.
Brief Summary: Bronchoscopy is performed on a daily basis for diagnostic and therapeutic purposes. This procedure may cause anxiety and discomfort requiring the use of sedative drugs.

In this study the investigators titrate the administration of sedatives using bispectral analysis of the EEG. The investigators compared 2 drugs, propofol versus midazolam regarding patient subjective tolerance, recovery of brain function, safety and operator's satisfaction.


Options:
A: electroencephalographic (BIS) and functional cognitive recovery (24h)
B: evaluation of intra-operative awareness in all the patients investigated (within 4 days after the general anesthesia)
C: Bispectral index (BIS) monitoring in abdominal surgery patients (six months)
D: Percentage of time with BIS in the desired range (During the procedure)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Double-blind, Randomised, Placebo-controlled Study Comparing the Efficacy and Safety of Two Fixed Dosages of a Novel Antidepressant Compound to That of Placebo in Patients With Major Depressive Disorder
Brief Summary: The purpose of this Venlafaxine-referenced study is to evaluate the efficacy, safety and tolerability of two fixed doses of Vortioxetine in the acute treatment of Major Depressive Disorder (MDD).


Options:
A: Change From Baseline in HAM-D-24 Total Score After 8 Weeks of Treatment (Baseline and Week 8)
B: Change From Baseline in MADRS Total Score After 6 Weeks of Treatment (Baseline and Week 6)
C: Change From Baseline to Week 8 in DSST (Number of Correct Symbols) and RAVLT (Acquisition and Delayed Recall) Using the Composite Z-score Defined as the Weighted Sum of the Individual Patient Z-scores (Baseline and Week 8)
D: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score (Baseline and Week 8)

Answer: B